SCHEMBL70291

SCHEMBL70291

c1ccc(COCOCOCOCOCc2ccccc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.74
IDO1 P14902 1/20 0.52
AGXT P21549 1/20 0.50
ALDH1A1 P00352 3/20 0.48
CA1 P00915 5/20 0.47
CA2 P00918 3/20 0.47
CA9 Q16790 3/20 0.47
CA7 P43166 2/20 0.47
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
MAPK1 P28482 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CA12 O43570 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A3 Q01959 1/20 0.46
KMT2A Q03164 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
TACR1 P25103 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL53267 1.00 TSHR (0.74) TSHRIDO1AGXTALDH1A1CA1
SCHEMBL223907 0.97 TSHR (0.78) TSHRIDO1AGXTALDH1A1CA1
SCHEMBL434644 0.91 TSHR (0.61) TSHRIDO1AGXTALDH1A1CA1
SCHEMBL434643 0.89 TSHR (0.58) TSHRIDO1AGXTALDH1A1CA1
SCHEMBL5353833 0.85 TSHR (0.61) TSHRIDO1AGXTALDH1A1CA1
SCHEMBL4675777 0.85 TSHR (0.61) TSHRIDO1AGXTALDH1A1CA1
SCHEMBL71046 0.85 TSHR (0.61) TSHRIDO1AGXTALDH1A1CA1
SCHEMBL987625 0.85 TSHR (0.61) TSHRIDO1AGXTALDH1A1CA1
SCHEMBL5311581 0.85 TSHR (1.00) TSHRIDO1AGXTALDH1A1CA1
SCHEMBL27380 0.85 TSHR (1.00) TSHRIDO1AGXTALDH1A1CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1961750-B1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO CO LTD (JP) 2013-09-18 EP disclosed
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1961750-A1 VLA-4 INHIBITORY DRUG Daiichi Sankyo Company, Limited (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 TSHR 2972/4885IDO1 3042/4885AGXT 3363/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 TSHR 3047/4885IDO1 3142/4885AGXT 3395/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 TSHR 3028/4885IDO1 3688/4885AGXT 3370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.